Catalyst Pharma Files 8-K on Material Agreement; Details Pending

TL;DR

**Catalyst Pharma filed an 8-K about a material agreement, but gave no details, leaving investors guessing.**

AI Summary

On January 4, 2024, Catalyst Pharmaceuticals, Inc. filed an 8-K to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While the filing indicates a significant event, it does not provide specific details about the agreement itself, such as names, dollar amounts, or the nature of the transaction. This lack of detail means investors are currently in the dark about the specifics of this material agreement, which could impact the company's future prospects and stock value.

Why It Matters

This filing signals a significant corporate event for Catalyst Pharmaceuticals, Inc., but without specific details, investors cannot assess its potential impact on the company's financial health or strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates a material event without providing specifics, creating uncertainty and potential for significant market reaction once details are disclosed.

Analyst Insight

A smart investor would monitor Catalyst Pharmaceuticals, Inc. for subsequent filings or press releases that provide specific details about the 'Material Definitive Agreement' before making any investment decisions, as the current filing lacks actionable information.

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of the earliest event reported
• Delaware (company) — state of incorporation for Catalyst Pharmaceuticals, Inc.
• 001-33057 (dollar_amount) — Commission File Number for Catalyst Pharmaceuticals, Inc.
• 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134 (company) — address of principal executive offices for Catalyst Pharmaceuticals, Inc.

Forward-Looking Statements

• Catalyst Pharmaceuticals, Inc. will file an amendment or a subsequent 8-K with more details about the material definitive agreement. (CATALYST PHARMACEUTICALS, INC.) — high confidence, target: 2024-02-04
• The stock price of Catalyst Pharmaceuticals, Inc. may experience volatility upon the release of specific details regarding the material definitive agreement. (CATALYST PHARMACEUTICALS, INC.) — medium confidence, target: 2024-03-04

FAQ

Key Financial Figures

• $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
• $15.00 — hares "), at a public offering price of $15.00 per share, less underwriting discounts,
• $140.1 m — ompany are expected to be approximately $140.1 million, after deducting underwriting dis
• $161.3 million — ayable by the Company, or approximately $161.3 million if the Underwriters exercise their opti

Filing Documents

• d149661d8k.htm (8-K) — 32KB
• d149661dex11.htm (EX-1.1) — 189KB
• d149661dex51.htm (EX-5.1) — 11KB
• d149661dex991.htm (EX-99.1) — 8KB
• d149661dex992.htm (EX-99.2) — 8KB
• g149661g0106000430491.jpg (GRAPHIC) — 2KB
• 0001193125-24-003489.txt ( ) — 438KB
• cprx-20240104.xsd (EX-101.SCH) — 3KB
• cprx-20240104_lab.xml (EX-101.LAB) — 18KB
• cprx-20240104_pre.xml (EX-101.PRE) — 11KB
• d149661d8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement On January 4, 2024, Catalyst Pharmaceuticals, Inc. (the " Company ") entered into an Underwriting Agreement (the " Underwriting Agreement ") with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement (collectively, the " Underwriters "), relating to the public offering, issuance and sale (the " Offering ") by the Company of 10,000,000 shares of the Company's common stock, par value $0.001 per share (the " Shares "), at a public offering price of $15.00 per share, less underwriting discounts, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-274427) and a related prospectus supplement filed with the Securities and Exchange Commission. Pursuant to the Underwriting Agreement, the Company also granted the Underwriters the right to purchase an additional 1,500,000 Shares within 30 days of January 4, 2024 at the public offering price, less underwriting discounts. The Company expects the offering to close on January 9, 2024, subject to the satisfaction of customary closing conditions. The net proceeds to the Company are expected to be approximately $140.1 million, after deducting underwriting discounts and estimated offering expenses payable by the Company, or approximately $161.3 million if the Underwriters exercise their option to purchase additional Shares in full. The Company intends to use the net proceeds of the Offering (i) to fund the potential acquisition of new product candidates, and (ii) for general corporate purposes. The underwriting agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including with respect to liabilities under the Securities Act of 1933, as amended, as well as customary termination provisions. In addition, subject to certai

01

Item 7.01. Regulation FD Disclosure On January 4, 2024, the Company issued a press release announcing the commencement of the Offering. On January 5, 2024, the Company issued a press release announcing the specific terms and conditions of the Offering. Each of these press releases are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated in this Item 7.01, including the press releases furnished herewith as Exhibit 99.1 and Exhibit 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. 2

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 1.1 Underwriting Agreement dated January 4, 2024, between Catalyst Pharmaceuticals, Inc. and BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule I thereto. 5.1 Opinion of Akerman LLP. 23.1 Consent of Akerman LLP (included in Exhibit 5.1). 99.1 Press release issued by the Company on January 4, 2024. 99.2 Press release issued by the Company on January 5, 2024. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Richard J. Daly Richard J. Daly President and CEO Dated: January 5, 2024 4

View Full Filing

View this 8-K filing on SEC EDGAR